Lupus Nephritis - Biotech, Pharma and Life Science Channel
PubMed Articles
Recommendation for use of belimumab for systemic lupus erythematosus.
The central role of B-lymphocytes in the pathogenesis of systemic lupus erythematosus (SLE) has turned the attention particularly to more specific B-cell targeted therapies in recent years. Belimumab...
Available evidence and outcome of off-label use of rituximab in clinical practice.
PURPOSE: To analyze the therapeutic indications for off-label use of rituximab, the available evidence for its use, the outcomes, and the cost. METHODS: This was a retrospective analysis of patients t...
The NZM2410 Sle2c1 lupus susceptibility locus is responsible for the expansion of the B1a cell compartment, and for the induction of T-cell induced renal and skin pathology on a CD95-deficient (Fas(lp...
Aortic thrombus and multiple embolisms during a Mycoplasma pneumoniae infection.
We report the case of a patient who presented with a thrombus of the aortic arch complicated with splenic, renal and peroneal artery embolisms, associated with transient lupus anticoagulant, during a...
Trichinella infections in different host species of an endemic district of Serbia.
Trichinella infections are endemic in the Balkan region of Europe. Though trichinellosis and agents thereof are serious problems for human health and animal husbandry, only a limited number of Trichin...
A 35-year-old Japanese female patient with systemic lupus erythematosus (SLE) presented with fever, erythematous papules and nodules, and polyarthralgia. Skin biopsy of a nodule was compatible with Sw...
Systemic lupus erythematosus-related pancreatitis in children.
We report on three patients who developed four episodes of acute pancreatitis while their systemic lupus erythematosus was active and being treated with prednisolone. In all three, gastritis was first...
Effects of hemoperfusion in the treatment of childhood Henoch-Schönlein purpura nephritis.
Purpose: Immune mediators play a role in the pathogenesis of Henoch-Schönlein purpura (HSP) nephritis. Since hemoperfusion (HP) is able to eliminate the immune mediators in many diseases, we investig...
Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis.
We describe a case of previously unreported autoimmune hepatitis and lupus-like syndrome induced by infliximab treatment for chronic plaque psoriasis. The condition resolved after withdrawal of inflix...
Tocilizumab is a highly effective therapeutic agent for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis. Furthermore, a large amount of case study data reveals that to...
News Articles
Autoantibodies may form basis of lupus diagnostic test
Scientists believe a new diagnostic test for lupus could be developed by looking for the presence of certain antibodies in the blood.Antibodies are proteins manufactured by the immune system to help i...
NEW YORK, May 22, 2013 /PRNewswire/ -- The Lupus Research Institute (LRI) today is hosting the first international conference devoted to advancing new treatments for lupus nephritis, a serious ki...
ImmuPharma secures £50m to develop ex-Cephalon asset
ImmuPharma has secured a £50 million, five-year equity financing facility to fund its late stage lupus treatment. This will allow the company to complete Phase III development of Lupuzor. Lupuzor (p...
UPDATE: ImmuPharma strengthens hand with £50mln financing deal
ImmuPharma has agreed a £50mln equity drawdown facility, one of the biggest deals of its kind in London, to fund the late-stage development of Lupuzor, its breakthrough drug for auto-immune dise...
Lupus Support Group Meeting in Lapeer on June 11th
Lapeer, MI (PRWEB) May 21, 2013 The Michigan Lupus Foundation will be holding a lupus Support Group meeting in Lapeer on June 11th. Meeting Details: Tuesday, June 11th 7:00pm â 8:3...
SuppreMol Raises € 9.5 million in Extended Series D Financing Round
SuppreMol GmbH / SuppreMol Raises € 9.5 million in Extended Series D Financing Round . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this anno...
Running Out of Lupus Drug Options: A Case
Jonathan Kay reports the case of a woman who is proving to be intolerant of lupus treatments. Medscape Rheumatology
ImmuPharma agrees £50mln financing deal to take drug into final phase clinical trials
ImmuPharma has agreed a £50mln equity drawdown facility, one of the biggest deals of its kind in London, to fund the late-stage development of Lupuzor, its breakthrough drug for auto-immune dise...
TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
BOSTON, May 17, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest update for their competitive landscape map for the Chronic Kidney Disease (CKD) market. This particula...
Events
None
Companies
Ignyta, Inc., located in San Diego, California, is a personalized medicine company developing revolutionary new products and services to customize diagnosis and treatment of patie...
The International Society for Interferon and Cytokine Research (ISICR), based in Bethesda, Md., is a non-profit organization devoted to interferon, cytokine and chemokine r...
Lupus Foundation of America, Inc. (LFA)
The LFA is the foremost national nonprofit health organization dedicated to finding the causes of and cure for lupus, and providing support, services, and hope to all people affec...
The LFA is the foremost national nonprofit voluntary health organization dedicated to finding the causes of and cure for lupus, and providing support, services, and hope to all pe...
Lupus Foundation of America (LFA)
The Lupus Foundation of America (LFA) is the foremost national nonprofit organization dedicated to finding the causes of and cure for lupus, and providing support, services, and h...
ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop nov...
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of RSLV-125, its novel tar...
Lupus Foundation of America, Inc.
Adamis Pharmaceuticals Corporation
La Jolla Pharmaceutical Company is a biopharmaceutical company. La Jolla had historically focused substantially all of its research, development and clinical efforts and financial...
Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, i...
Clinical Trials
Autoimmunity in Sisters of Lupus Patients
This study enrolled over 400 unaffected sisters of young women diagnosed with SLE. These unaffected sisters are being followed with an annual health questionnaire (CSQ) and blood sample.
The purpose of this study is to evaluate the effect of DHEA on endothelial dysfunction in patients with systemic lupus by measuring: 1. changes in brachial artery flow-mediated dilatati...
Several studies have shown that persons with systemic lupus erythematosus (SLE) have poor general health and a higher risk of heart attack and bone loss (osteoporosis) compared to the gene...
Although SLE and RA are correlated with genetic predisposing factors such as human leukocyte antigen (HLA) class II, both diseases and other genetic factors might have contributed to the d...
Triptorelin for Ovary Protection in Childhood Onset Lupus
The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic...
The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic...
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
This study will examine a new approach to treating patient with severe systemic lupus erythematosus (SLE) that involves collecting stem cells (cells produced by the bone marrow that develo...
Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodie...
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
High cholesterol levels are common in people with Systemic Lupus Erythematosus (SLE). Atorvastatin is a drug that reduces cholesterol levels. This study will test whether atorvastatin can...
Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy
This study will evaluate the safety and effectiveness of a new immunosuppressive drug, sirolimus, in reducing the amount of protein in the urine in patients with membranous nephropathy. T...
Videos
Lupus and the Kidneys - March 2012
Learn about the symptoms and treatments of lupus nephritis from two women living with systemic lupus erythematosus and kidney involvement.
Medical and Biotech [MESH] Definitions
Aristolochic Acids
Nitro-phenanthrenes occurring in ARISTOLOCHIACEAE and other plants. They derive from stephanine (APORPHINES) by oxidative ring cleavage. The nitro group is a reactive alkylator (ALKYLATING AGENTS) that binds to biological macromolecules. Ingestion by humans is associated with nephropathy (NEPHRITIS). There is no relationship to the similar named aristolochene (SESQUITERPENES).
Leptospira Interrogans Serovar Canicola
A serovar of the bacterial species LEPTOSPIRA INTERROGANS, whose natural host is DOGS where disease is characterized by GASTROENTERITIS, and INTERSTITIAL NEPHRITIS.
Procainamide
A derivative of PROCAINE with less CNS action. It also acts as a non-nucleoside inhibitor of DNA METHYLATION and has led to SYSTEMIC LUPUS ERYTHEMATOSUS.
Tuberculosis, Cutaneous
Tuberculosis of the skin. It includes scrofuloderma and tuberculid, but not LUPUS VULGARIS.
Glomerulonephritis, Membranoproliferative
Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.
